Hilltelligence markHilltelligence
Archived This bill is from the 117th Congress (2021–2022) and is no longer under active consideration.
Bills/H.R. 7640117th Congress

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

House: Referred
Companion bill: S. 4348(Related bill)
Cosponsors
0
Introduced
2022-05-03
Last action
2022-05-03

Referred to the House Committee on Energy and Commerce.

Sign in to view Hilltelligence’s plain-English summary.

Action Timeline
  1. HouseLatest

    Referred to the House Committee on Energy and Commerce.

  2. House

    Introduced in House

Sign in to view Hilltelligence’s passage-probability analysis.

Official Sources
Topics

Policy area

Health

Sign in to view Hilltelligence’s potential-cosponsor analysis.